First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

被引：34

作者：

S. Baldari

F. Ferraù

C. Alafaci

A. Herberg

F. Granata

V. Militano

F. M. Salpietro

F. Trimarchi

S. Cannavò

机构：

[1] Department of Radiological Sciences, Unit of Nuclear Medicine, University of Messina, Messina

[2] Department of Medicine and Pharmacology, Section of Endocrinology, University of Messina

[3] Department of Neurological Sciences, Unit of Neurosurgery, University of Messina, Messina

[4] Department of Radiological Sciences, University of Messina, Messina

来源：

Pituitary | 2012年 / 15卷 / Suppl 1期

关键词：

111Indium-DTPA-octreotide; Cabergoline resistance; Giant prolactinoma; Peptide receptor radionuclide therapy; PRL-secreting pituitary adenoma;

D O I：

10.1007/s11102-011-0373-5

中图分类号：

学科分类号：

摘要：

In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment. © 2012 Springer Science+Business Media, LLC.

引用

页码：S57 / S60

页数：3

共 30 条

[1]

Colao A., Di Sarno A., Pivonello R., Di Somma C., Lombardi G., Dopamine receptor agonists for treating prolactinomas, Expert Opin Investig Drugs, 11, pp. 787-800, (2002)

[2]

Colao A., Pituitary tumours: The prolactinoma, Best Pract Res Clin Endocrinol Metab, 23, pp. 575-596, (2009)

[3]

Gillam M.P., Molitch M.E., Lombardi G., Colao A., Advances in the treatment of prolactinomas, Endocr Rev, 27, 5, pp. 485-534, (2006)

[4]

Acosta-Gomez M.J., Muros M.A., Llamas-Elvira J.M., Ramirez A., Ortega S., Sabatel G., Ramos C., De La Riva-Aguilar A., The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours, Br J Radiol, 78, 926, pp. 110-115, (2005)

[5]

Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A., Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas, J Clin Endocrinol Metab, 84, 9, pp. 3268-3276, (1999)

[6]

Corsello S.M., Ubertini G., Altomare M., Lovicu R.M., Migneco M.G., Rota C.A., Colosimo C., Giant Prolactinomas in men: Efficacy of cabergoline treatment, Clin Endocrinol, 58, pp. 662-670, (2003)

[7]

Shimon I., Benbassat C., Hadani M., Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men, Eur J Endocrinol, 156, 2, pp. 225-231, (2007)

[8]

Acharya S.V., Gopal R.A., Menon P.S., Bandgar T.R., Shah N.S., Giant prolactinoma and effectiveness of medical management, Endocr Pract, 16, 1, pp. 42-46, (2010)

[9]

Cannavo S., Bartolone L., Blandino A., Spinella S., Galatioto S., Trimarchi F., Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline, J Endocrinol Invest, 22, 4, pp. 306-309, (1999)

[10]

Byrne S., Karapetis C., Vrodos N., A novel use of temozolomide in a patient with malignant prolactinoma, J Clin Neurosci, 16, 12, pp. 1694-1696, (2009)

← 1 2 3 →